franckreporter/iStock via Getty Images
- Chenghe Acquisition (CHEA) +153%.
- 4D Molecular Therapeutics (FDMT) +54%.
- BioRestorative Therapies (BRTX) +26% Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease.
- Everbridge (EVBG) +18% Enters into Definitive Agreement to Be Acquired by Thoma Bravo for $1.5 Billion.
- Calamp (CAMP) +10%.
- Reborn Coffee (REBN) +16%.
- Estee Lauder (EL) +16% Q2 earnings call release
- Adverum Biotechnologies (ADVM) +15% Announces $127.5 Million Private Placement Financing.
- Catalent (CTLT) +11%.
- MicroCloud Hologram (HOLO) +9%.
- Cadrenal Therapeutics (CVKD) +10%.
- Smart for Life (SMFL) +10%.
- BioXcel Therapeutics (BTAI) +11%.
- OneMedNet (ONMD) +8%
- Elanco Animal Health (ELAN) +8% buy Elanco’s aqua business for $1.3B in cash.
- Core Scientific (CORZ) +7%.
- Rani Therapeutics Holdings (RANI) +12%.
- Aclarion (ACON) +6%.
- Alto Neuroscience (ANRO) +6%.
- Clearmind Medicine (CMND) +19%.
- Tyson Foods (TSN) +5% rallies after smashing profit expectations despite slowing price inflation.